Abstract:Hyperinsulinism of infancy is a major cause of persistent hypoglycaemia in the newborn period. Transient mild self-limiting hyperinsulinaemia and hypoglycaemia have been described in neonates born to mothers taking ritodrine therapy for premature labour. Ritodrine crosses the placental barrier and enters the fetal circulation readily but the mechanism of how it causes hyperinsulinaemia and hypoglycaemia is unclear. We report the case of severe prolonged hyperinsulinaemic hypoglycamia in a neonate born to a mot… Show more
“…The times of additional interventions in these case reports vary greatly from within the first 36 hours of life 23 to 7 to 10 days of life. 24 It may be prudent to delay additional therapies as long as possible (up to 14 days of life) to allow the transient forms of hypoglycemia to resolve in order not to expose infants to unnecessary drug therapy. Other than the infant who continues to experience consistent episodes of hypoglycemia or requires persistently high dextrose concentrations (>D25%), most infants should remain on dextrose infusions for at least 7 to 10 days before the addition of other therapeutic options is considered.…”
Section: Dextrosementioning
confidence: 99%
“…This treatment approach has been discussed more recently in the literature in patients fro whom other therapeutic options have failed; however, only 4 patients have been described in the published case series. 24,48,49 Nifedipine was initiated at 0.25 to 0.3 mg/kg/day, orally, divided every 8 hours. Doses were increased by 0.1 mg/kg/day until patients were euglycemic and dextrose was weaned.…”
While hypoglycemia occurs commonly among neonates, treatment can be challenging if hypoglycemia persists beyond the first few days of life. This review discusses the available treatment options for both transient and persistent neonatal hypoglycemia. These treatment options include dextrose infusions, glucagon, glucocorticoids, diazoxide, octreotide, and nifedipine. A stepwise, practical approach to the management of these patients is offered.
“…The times of additional interventions in these case reports vary greatly from within the first 36 hours of life 23 to 7 to 10 days of life. 24 It may be prudent to delay additional therapies as long as possible (up to 14 days of life) to allow the transient forms of hypoglycemia to resolve in order not to expose infants to unnecessary drug therapy. Other than the infant who continues to experience consistent episodes of hypoglycemia or requires persistently high dextrose concentrations (>D25%), most infants should remain on dextrose infusions for at least 7 to 10 days before the addition of other therapeutic options is considered.…”
Section: Dextrosementioning
confidence: 99%
“…This treatment approach has been discussed more recently in the literature in patients fro whom other therapeutic options have failed; however, only 4 patients have been described in the published case series. 24,48,49 Nifedipine was initiated at 0.25 to 0.3 mg/kg/day, orally, divided every 8 hours. Doses were increased by 0.1 mg/kg/day until patients were euglycemic and dextrose was weaned.…”
While hypoglycemia occurs commonly among neonates, treatment can be challenging if hypoglycemia persists beyond the first few days of life. This review discusses the available treatment options for both transient and persistent neonatal hypoglycemia. These treatment options include dextrose infusions, glucagon, glucocorticoids, diazoxide, octreotide, and nifedipine. A stepwise, practical approach to the management of these patients is offered.
“…None of the infants were prenatally exposed to maternal drugs associated with neonatal hyperinsulinism, such as ritodrine or thiazide diuretics [16]. Perinatal complications that commonly predispose to prolonged neonatal hyperinsulinism, such as IUGR or severe asphyxia [6,7,17] were absent in all infants.…”
This patient series reports on prolonged hyperinsulinism in four newborn infants without characteristic perinatal risk factors. The condition presented with asymptomatic hypoglycemia soon after birth and was accompanied by inappropriately elevated plasma insulin levels and suppressed ketogenesis and lipolysis. Glucose infusion rates between 11 and 20 mg/kg/min were necessary for correction of hypoglycemia. Sustained euglycemia could be achieved only after starting diazoxide. In all infants, diazoxide could be weaned off within weeks without the recurrence of hypoglycemia. This case series illustrates the varied perinatal history and clinical course of prolonged neonatal-onset hyperinsulinism and highlights the importance of considering this condition in infants without typical predisposing factors.
“…71 In one case, hypoglycemia was severe and recurrent. 72 Dose-response gradient: no dose effect has been evaluated.…”
Section: Selective and Nonselective β-Blockers (β-Adrenergic Receptor...mentioning
confidence: 99%
“…74 Management: the management of severe transient hyperinsulinemic hypoglycemia in a neonate born to a mother taking ritodrine from 16 weeks of gestation for preterm labor required treatment with continuous IV glucose infusion (up to 12 mg/kg/min) and oral nifedipine. 72 Quality of the studies: the available data derive mainly from retrospective studies or case series with small sample sizes.…”
Section: Selective and Nonselective β-Blockers (β-Adrenergic Receptor...mentioning
The prompt identification of at-risk newborns for drug-induced hypoglycemia can minimize the risk for adverse side effects, inappropriate investigations, and considerable unnecessary costs. Existing literature discusses drug-induced hypoglycemia, but a systematic description of neonatal hypoglycemia induced or exacerbated by maternal medications is missing. We reviewed the association between neonatal hypoglycemia and maternal medications. We systematically searched the literature according to the PICOS model on drug-induced hypoglycemia in neonates born to nondiabetic women treated with medications during the pregnancy or the labor. The main outcomes of the review were: (1) prevalence of hypoglycemia, (2) risk factors and potential confounders, (3) time at onset and severity of hypoglycemia, (4) dose–response gradient, (5) metabolic features of hypoglycemia, (6) modalities to treat hypoglycemia, and (7) quality of the studies. We included 69 studies in this review and we identified 11 groups of maternal drugs related to neonatal hypoglycemia. Results were classified for each outcome. Our review aims at supporting clinicians in the identification of the newborn at risk for hypoglycemia and in the differential diagnosis of neonatal hypoglycemia. Further studies are necessary to assess the risk of neonatal hypoglycemia associated with common maternal medications.
Key Points
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.